Fiche publication
Date publication
mai 2006
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAUCHESNE Patrick
Tous les auteurs :
Beauchesne P, Pedeux R, Soler C
Résumé
Malignant glioma, the main primary brain tumor, has a dismal prognosis. Current therapies extend a patient's survival (usually 2-3 months) by only about 9 months to 1 year on average. Early and reliable assessment of an individual patient's prognosis and response to therapeutics is therefore essential to determine whether continued therapies are beneficial. Functional imaging methods have been proposed for the evaluation of treatment efficacy and are claimed to be more specific than are conventional radiological investigations. Yet the question remains as to how best to incorporate this newly acquired insight into the clinical context. SPECT and PET assess tumor viability by specific intracellular uptake in malignant cells. (TI-201)thallium SPECT accuracy is similar to that of (18)FDG PET. Tc-99m-MIBI is used as an alternative to (TI-201)thallium for the study of myocardial perfusion and has also been proposed as an imaging agent for various tumors such as gliomas. MIBI brain SPECT has shown more specificity and sensitivity than (TI-201)thallium brain SPECT. MIBI brain SPECT may help in differentiating a high grade glioma recurrence from a radiation necrosis. In this review, we describe the roles of MIBI SPECT in the management and follow up of malignant glioma patients.
Référence
Curr Med Imaging Rev. 2006 May;2(2):227-35.
